United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics (UTHR) has 5 years of Asset Writedowns and Impairment data on file, last reported at -$5.3 million in Q4 2022.

• For the quarter ending Q4 2022, Asset Writedowns and Impairment rose 94.37% year-over-year to -$5.3 million; the trailing twelve-month figure through Sep 2023 stood at -$5.3 million (up 94.27% YoY), and the FY2025 full-year result was $21.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$5.3 million in Q4 2022, from $1.7 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $6.1 million in Q1 2021 to a low of -$94.2 million in Q4 2021.
• A 4-year average of -$11.6 million and a median of $650000.0 in 2019 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment soared 1450.0% in 2020 and slumped 72.13% in 2022, its largest moves.
• Tracing UTHR's Asset Writedowns and Impairment over 4 years: stood at -$8.4 million in 2019, then surged by 164.29% to $5.4 million in 2020, then tumbled by 1844.44% to -$94.2 million in 2021, then soared by 94.37% to -$5.3 million in 2022.
• Business Quant data shows UTHR's Asset Writedowns and Impairment at -$5.3 million in Q4 2022, $1.7 million in Q1 2022, and -$94.2 million in Q4 2021.